MaxCyte IPO Presentation Deck

Executive Leadership with Broad Depth of Experience July 2021 Doug Doerfler President and Chief Executive Officer . Co-founded MaxCyte 1998; 20+ years developing MaxCyte's Flow Electroporation® technology Previously CEO of Immunican; various positions at Life Technologies Amanda Murphy, CFA Chief Financial Officer 15 years of equity research experience covering high science tools and diagnostics, cell and gene therapy ecosystem Ron Holtz, CPA Chief Accounting Officer 15 years at MaxCyte; previously public and private company CFO Previous experience in EY's Financial Advisory Services Group Maher Masoud, JD Executive Vice President and General Counsel 21 years as biotech industry attorney and general counsel: Wellstat: Rossi/Masoud LLC; Human Genome Sciences, Inc. Managed legal team/compliance on drug launches negotiated/executed 1,000+ clinical trial agreements, negotiated licensing deals valued at $300+ million Thomas M. Ross Executive Vice President, Global Sales 35+ years of successful sales, marketing and operations leadership in life science and clinical diagnostics markets Previously SVP Commercial Operations at OpGen; Chief Commercial Officer at Predictive BioScience: VP North America Medical Diagnostics Sales at Qiagen/Digene Corporation CONFIDENTIAL Board of Directors J. Stark Thompson, PhD Non-Executive Chairman Doug Doerfler Chief Executive Officer, MaxCyte Yasir Al-Wakeel, BM MCh Non-Executive Director Will Brooke Non-Executive Director M MaxCyte Richard Douglas, PhD Non-Executive Lead Director Stan Erck Non-Executive Director Rekha Hemrajani Non-Executive Director John Johnston Non-Executive Director Art Mandell Non-Executive Director life Luminex MaxCyte KRONOS Harbert Management HMC Corporation genzyme NOVAVAX ONYX EXELIXIS NOMURA seymour CODE pierce Human Genome Sciences

View entire presentation